Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

Published:2007-04-01 Issue:4 Volume:12 Page:426-437
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Strumberg Dirk¹,Clark Jeffrey W.²,Awada Ahmad³,Moore Malcolm J.⁴,Richly Heike¹,Hendlisz Alain³,Hirte Hal W.⁵,Eder Joseph P.⁶,Lenz Heinz-Josef⁷,Schwartz Brian⁸

Affiliation:

1. a Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany

2. b Massachusetts General Hospital Cancer Center, Boston, Massachusetts,USA

3. c Jules Bordet Institute, Brussels, Belgium

4. d Princess Margaret Hospital, Toronto, Ontario, Canada

5. e Juravinski Cancer Center, Hamilton, Ontario, Canada

6. f Dana-Farber Cancer Institute, Boston, Massachusetts, USA

7. g University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA

8. h Bayer Pharmaceuticals Corporation, West Haven, Connecticut, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the mechanisms of action of sorafenib.Discuss the safety and toxicity data from phase I trials of sorafenib.Evaluate phase I and II trials of sorafenib with activity data.Discuss future areas for research in the development of this drug. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-4-426

Reference68 articles.

1. Targeting RAS signalling pathways in cancer therapy;Downward;Nat Rev Cancer,2003

2. The Ras-Raf-MEK-ERK pathway in the treatment of cancer;Hilger;Onkologie,2002

3. Mutational analysis of the ARAF gene in human cancers;Lee;APMIS,2005

4. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention;Chang;Leukemia,2003

5. Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group;Bukowski;Clin Cancer Res,2004

Cited by 371 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explosomes: A new modality for DEB-TACE local delivery of sorafenib: In vivo proof of sustained release;Journal of Controlled Release;2023-12

2. Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma;Cell Communication and Signaling;2023-11-27

3. ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization;BMC Medicine;2023-09-25

4. MXene-Integrated Silk Fibroin-Based Self-Assembly-Driven 3D-Printed Theragenerative Scaffolds for Remotely Photothermal Anti-Osteosarcoma Ablation and Bone Regeneration;ACS Materials Au;2023-09-08

5. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance;International Journal of Molecular Sciences;2023-07-30